Abstract 17210: Von Willebrand Factor Level and Duration of Atrial Fibrillation
Background: We have recently reported that patients with non-valvular atrial fibrillation (NVAF) have CD40L - a marker of platelet and inflammation activity - significantly elevated only within the first year, but particularly first month of dysrhythmia. Relationship between Von Willebrand factor (VWF) level and duration of atrial fibrillation is poorly defined.
Methods: In order to determine if VWF is a time-dependent marker of prothrombotic status, plasma VWF antigen measured by latex immunoassay in 425 consecutive NVAF patients was analysed according to the duration of atrial fibrillation (< 1 month: n=76, 1-12 months: n=98, and >12 months: n=251) and compared to 100 controls with normal sinus rhythm (NSR).
Results: The mean VWF antigen level in NVAF patients with <1 month duration of dysrhythmia (167±59%) was not different compared to those with 1-12 months (157±50%, p=0.024), and >12 months duration (156±54%, p=0.11) but significantly higher compared to NSR controls (143±48%, p=0.003, see Figure). NVAF patients with higher CHA2DS2-VASc scores when divided into three values: 0, 1, or >2 had significantly elevated VWF level in all groups of dysrhythmia duration: <1 month (p<0.0001), 1-12 months (p=0.046), and >12 months (p=0.0004). Also higher intensity of spontaneous echocardiographic contrast was associated with significantly higher VWF level in all three groups of atrial fibrillation duration.
Conclusions: VWF remains steadily elevated throughout the course of dysrhythmia in NVAF patients with higher CHA2DS2-VASc scores and in those with higher intensity of left atrium blood stagnation.
Author Disclosures: K.P. Cohoon: None. E. Konik: None. R.D. McBane: None. R.M. Melduni: None. N.M. Ammash: None. S.J. Asirvatham: None. W.E. Wysokinski: None.
- © 2016 by American Heart Association, Inc.